Could your own immune cells fight lung cancer? new trial tests safety

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Eligibility of Participants: o Diagnosed histologically or cytologically with stage IIIB or stage IV non-small cell lung cancer (NSCLC) or patients with recurrence or progression following multimodal treatments (radiotherapy, surgical resection, or therapeutic chemoradiotherapy for locally advanced disease). * Have undergone at least two systemic therapies for advanced NSCLC, including platinum-based chemotherapy, anti-PD-1 therapy, and/or other targeted therapies. 2. At Least One Measurable Lesion: o The measurable lesion must not undergo radiotherapy during the cell therapy period. 3. Age: o ≥20 years. 4. Weight: o Between 40 and 100 kg. 5. Normal Blood Count (based on test results within 4 weeks before blood collection for cell preparation): o White blood cells (WBC): ≥3000/mm³. o Lymphocytes: ≥1000/mm³. * Hemoglobin: ≥10 g/dL. * Platelets: ≥100,000/mm³. 6. Normal Liver and Kidney Function (based on test results within 4 weeks before blood collection for cell preparation): * Creatinine: ≤1.25× the upper limit of normal (ULN). * Total bilirubin: ≤1.5× ULN. * SGOT (AST): ≤3× ULN. * SGPT (ALT): ≤3× ULN. 7. Informed Consent: o Participants must sign the consent form. 8. ECOG Performance Status: o Score of 0-1. 9. For Women of Childbearing Age: * Must agree to use effective contraception during the trial. Exclusion Criteria: 1. Positive Test Results for the Following Infections: o HCV (HCV antibody-positive). * HBV (HBsAg-positive). * HIV (HIV antibody-positive). * HTLV (HTLV antibody-positive). * Syphilis (Treponema pallidum antibody-positive). * Tuberculosis (TB culture-positive). 2. ECOG Performance Status: o Score of 2-4. 3. Albumin Intolerance: o Participants who cannot tolerate albumin. 4. Short Life Expectancy: o Life expectancy estimated by the physician to be less than 12 weeks. 5. Participation in Other Clinical Trials: o Within 30 days prior to entering this trial. 6. Pregnancy or Breastfeeding: o Positive pregnancy test or currently breastfeeding. 7. Other Medical Conditions: o Immunodeficiency, severe heart or lung dysfunction, coagulation disorders, unresolved side effects from prior cancer therapy (not recovered to CTCAE grade 1), prior transplant surgery, or deemed unsuitable by the physician. 8. Noncompliance: o Unable to adhere to follow-up or examination procedures. 9. Concurrent Cancer: o Other cancers diagnosed within the past 2 years. 10. Specific Complications: * Brain metastases, leptomeningeal disease, or spinal cord compression.